In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bayhill Therapeutics gets $35.4mm in Series B financing

Executive Summary

Bayhill Therapeutics (autoimmune and metabolic diseases) closed its Series B venture round, raising $35.4mm. De Novo Ventures and Lilly Ventures led, joined by existing investors CMEA Ventures, Latterell Venture Partners, Morgenthaler Ventures, US Venture Partners, and the Vertical Group.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies